VSTM

Health Technology

$3.71 -3.89%

Back to Screener

Live Volume

3,046,992

Market Cap

326.01 M

P/E Ratio

-

52W Peak Proximity

%33

ANALYSIS CENTER

GOD-TIER PROMPT ACTIVE

Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level

10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.

1Executive Summary

2Fair Value

3Fundamental Analysis

4Technical Analysis

5Scenario Analysis

6Competitor Comparison

7Dividend Return

8Risk Analysis

9Catalyst Calendar

10Action Plan

HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.

İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.

Open Advanced Chart

TradingView Charts

• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools

Broker Partners

Interactive Brokers

Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.

TD Ameritrade (Schwab)

Industry-leading trading platforms and comprehensive education.

All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — VSTM

Verastem, Inc. — Company Profile & Analysis

Verastem, Inc., founded in 2010 and headquartered in Needham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative, small-molecule drugs aimed at treating high-unmet-need cancers. Since its inception, the company has focused on the complex biology of the RAS/MAPK signaling pathway, a critical driver in numerous oncology indications. Verastem’s mission is to transform the lives of patients by addressing the compensatory mechanisms that allow cancer cells to survive and proliferate despite traditional therapeutic interventions, positioning itself as a specialized player in the precision oncology landscape.

The company’s primary product pipeline centers on two key assets: Avutometinib and Defactinib. Avutometinib is a potent, orally administered dual RAF/MEK inhibitor designed to block MEK kinase activity and prevent the compensatory reactivation of MEK by upstream RAF. When combined with Defactinib, an oral small-molecule inhibitor of FAK (focal adhesion kinase) and proline-rich tyrosine kinase, the company aims to provide a synergistic therapeutic effect. This combination is currently being evaluated in several high-profile clinical trials, including RAMP 201 and RAMP 301, which focus on recurrent low-grade serous ovarian cancer, as well as the RAMP 203 trial, which explores the combination of Avutometinib with Amgen’s LUMAKRAS for KRAS-G12C mutant cancers.

Verastem occupies a strategic niche in the biopharmaceutical market by leveraging a robust network of global collaborations. By maintaining license agreements with industry giants such as Chugai Pharmaceutical and Pfizer, as well as clinical collaborations with Amgen and GenFleet Therapeutics, the company effectively de-risks its development programs while expanding its reach into diverse patient demographics. Its target demographic includes patients with solid tumors driven by RAS pathway mutations, a significant and difficult-to-treat segment of the oncology market. The company’s focus on 'co-pack' therapeutic strategies, such as AVMAPKI and FAKZYNJA, reflects a commitment to integrated treatment regimens that address the biological complexity of cancer.

Looking toward the future, Verastem is strategically positioned to advance its lead programs through late-stage clinical development and potential regulatory filings. The company’s focus on the RAMP (RAF/MEK/FAK) platform represents a long-term commitment to establishing a new standard of care for patients with RAS-driven malignancies. By continuously refining its pipeline and fostering discovery-stage partnerships, such as the collaboration with GenFleet, Verastem aims to sustain its growth trajectory. The company’s ability to navigate the regulatory environment while maintaining a lean, research-focused operational model will be critical as it transitions from a development-stage entity toward potential commercialization.

Economic Moat Verastem’s competitive advantage lies in its specialized focus on the RAS/MAPK signaling pathway and its proprietary combination therapy platform, which addresses the critical issue of compensatory resistance in cancer cells. By securing strategic intellectual property and high-value clinical collaborations with major pharmaceutical entities like Pfizer and Amgen, the company creates significant barriers to entry for competitors attempting to replicate its synergistic RAF/MEK/FAK inhibitor approach.

CEO Mr. Daniel W. Paterson

Employees 102

Headquarters United States

Market Competitors

CLVS CRSP EDIT BLUE GTHX

Smart Tags

#VSTM #Biotech #Oncology #NASDAQ #PrecisionMedicine #CancerResearch #ClinicalTrials

Market Insights & Investor Q&A — VSTM

Frequently Asked Questions

How can I use AI-powered ready-made templates to analyze the VSTM stock?

On the DocuRefinery platform you will find a no‑signup, free template that works with verified data for VSTM. Just enter the ticker, select risk analysis or dividend yield options, and the AI generates a detailed report in seconds.

What prompt should I use to get a hallucination‑free dividend yield analysis for VSTM?

Choose the ready-made prompt that includes "dividend yield" and "verified data" filters. The AI scans VSTM's historical payouts, applies a calibrated model, and returns an accurate yield estimate without any AI hallucinations.

Can I perform a portfolio stress test for VSTM using a free AI tool?

DocuRefinery offers an instant, no‑registration stress‑test template. Add VSTM to your portfolio, set the market scenarios, and the AI instantly runs a risk simulation, delivering a clear, actionable report.

Deep Analysis

AI‑Enabled Ready Solutions for VSTM Investment Analysis

When evaluating a single ticker like VSTM, AI methodologies such as risk modeling, trend detection, and balance‑sheet scanning provide a clear edge over traditional spreadsheet work. While manual analysis can take hours, AI‑driven ready prompts deliver comprehensive insights in moments.

DocuRefinery lets investors leverage its instant, free, no‑signup templates to run deep dives on VSTM. A single command pulls verified data, runs AI simulations across multiple scenarios, and presents the results in an easy‑to‑read format.

The advantage of an AI approach lies in its ability to produce hallucination‑free, data‑driven outcomes quickly. Using ready-made prompts, you can monitor VSTM's volatility profile, dividend yield, and market sensitivity with just a few clicks.

Through prompt engineering, users can tailor their analysis to specific strategies. For example, combine VSTM's historical performance with verified data filters to build a custom forecast model, then execute it instantly on DocuRefinery for fast, reliable decision support.